The FDA has given HealthPartners a fast-track for testing of a drug aimed at combating COVID-19. The study will include up to 60 hospitalized patients with COVID-19 pneumonia. Dr. Charles Bruen says the hope is that the drug will be an effective way…

“To prevent or help tamp down that severe inflammation, to help minimize the long-term lung damage that a patient may have.”

Dr. Bruen says if effective, the drug could potentially reduce lung damage and the need for a ventilator for some patients–and could even save lives.